Taro Pharmaceutical Industries Ltd. (TARO)

Market Cap	1.59B
Revenue (ttm)	610.83M
Net Income (ttm)	45.70M
Shares Out	37.58M
EPS (ttm)	1.22
PE Ratio	34.61
Forward PE	9.81
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,414
Open	42.15
Previous Close	42.23
Day's Range	42.14 - 42.41
52-Week Range	24.69 - 45.76
Beta	0.61
Analysts	Hold
Price Target	43.00 (+1.9%)
Earnings Date	May 21, 2024

About TARO

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1959
• Employees: 1,554
• Stock Exchange: NYSE
• Ticker Symbol: TARO

Financial Performance

In 2022, TARO's revenue was $572.95 million, an increase of 2.07% compared to the previous year's $561.35 million. Earnings were $25.45 million, a decrease of -56.33%.

Analyst Forecast

According to one analyst, the rating for TARO stock is "Hold" and the 12-month stock price forecast is $43.0.

Price Target

$43.0

(1.90% upside)

Analyst Consensus: Hold